La Jolla Pharmaceuticals Co (LJPC) Common Stock USD0.0001
La Jolla Pharmaceutical Company is engaged in development and commercialization of therapies for patients suffering from life-threatening diseases. Its product pipeline include GIAPREZA (angiotensin II) and XERAVA (eravacycline). Its GIAPREZA (angiotensin II) injection is a vasoconstrictor indicated to increase blood pressure in adults with septic or other distributive shock. The GIAPREZA is used for the treatment of refractory hypotension in adults with septic or other distributive shock. Its XERAVA (eravacycline) is a tetracycline class antibacterial indicated for the treatment of complicated intra-abdominal infections (cIAI) in adults. The Company's early-stage clinical development product candidate include TP-6076, TP-271, and TP-2846. Its TP-6076 is a IV formulation of a fully synthetic fluorocycline derivative for the treatment of certain multidrug-resistant gram-negative bacteria. Its TP-2846, an IV formulation of a tetracycline for the treatment of acute myeloid leukemia.
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.